| Identification | Back Directory | [Name]
NAPHTHOFLUORESCEIN | [CAS]
61419-02-1 | [Synonyms]
NAPHTHOFLUORESCEIN
Naphthafluorescein
NAPHTHOFLUORESCEIN, FOR FLUORESCENCE
NAPHTHOFLUORESCEIN FOR FLUORESCENCE 95+%
Spiro[7H-dibenzo[c,h]xanthene-7,1'(3'H)-isobenzofuran]-3'-one,3,11-dihydroxy- | [EINECS(EC#)]
634-716-5 | [Molecular Formula]
C28H16O5 | [MDL Number]
MFCD00329026 | [MOL File]
61419-02-1.mol | [Molecular Weight]
432.42 |
| Hazard Information | Back Directory | [Uses]
Naphthofluorescein is a furin inhibitor. | [Uses]
Naphtofluorescein is a pH-sensitive fluorescent probe, also used for preparation of labels and enzyme substrates.
| [Definition]
ChEBI: Naphthofluorescein is a member of xanthenes. | [in vivo]
Naphthofluorescein (compound 19) (100 mg/kg; i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks)does not show weight loss or apparent histological abnormalities in the lung, liver, and kidney, or cause cause severe adverse effects for at least 2 weeks in mice[1].
Naphthofluorescein (compound 19) (100 mg/kg; i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks) strikingly suppresses the tumour growth of subcutaneously injected E0771 cells and significantly attenuates tumour growth of MDA-MB-231 and AsPC-1 cells in immunodeficient mice. In turn, naphthofluorescein does not attenuate tumour growth of FIH-1-depleted MDA-MB-231 cells[1].
Naphthofluorescein (compound 19) (100 mg/kg; i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks) suppresses tumour growth in human cancer cells in an FIH-1-dependent manner[1]. | Animal Model: | Male C57BL/6J mice (8 weeks)[1] | | Dosage: | 100 mg/kg | | Administration: | i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks | | Result: | Neither showed weight loss or apparent histological abnormalities in the lung, liver, and kidney, or caused cause severe adverse effects for at least 2 weeks in mice.
|
| Animal Model: | Female C57BL/6J mice (E0771) and BALB/c nude mice (HT1080, MDA-MB-231, and AsPC-1) (6 weeks)[1] | | Dosage: | 100 mg/kg | | Administration: | i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks | | Result: | Strikingly suppressed the tumour growth of subcutaneously injected E0771 cells and significantly attenuated tumour growth of MDA-MB-231 and AsPC-1 cells in immunodeficient mice. In turn, naphthofluorescein did not attenuate tumour growth of FIH-1-depleted MDA-MB-231 cells.
|
| [storage]
Store at -20°C |
|
|